Clinical Trials Logo

Filter by:
NCT ID: NCT04704999 Not yet recruiting - Clinical trials for Plasmodium Vivax Malaria

Southeast Asia Dose Optimization of Tafenoquine

SEADOT
Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg/kg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg/kg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoquine in Southeast Asia.

NCT ID: NCT04595656 Not yet recruiting - Clinical trials for Cause of Neonatal Death

Defining Causes of Deaths in South and Southeast Asia

SEACTN-VA
Start date: December 1, 2020
Phase:
Study type: Observational

Mortality data are important in low and middle-income countries to assess the population health status and trends. Mortality statistics in the populations of Bangladesh, Myanmar and Lao PDR are considered as generally limited and a recent assessment of vital registration systems of those countries reported a poor performance of the death registration system. Majority of deaths occur at home in rural area of those countries without cause of death assigned. To address this problem, the investigators will use verbal autopsy (VA) method developed by WHO to ascertain the cause of a death based on an interview with a family member or caregiver of deceased person to obtain information about causes of death in study rural communities. Death related to a specific cause will be defined by ICD-10 codes and described as primary, secondary or underlying COD. The study is planned to conduct in approximately 390 rural village communities covered by Southeast Asia clinical trial network (SEACTN) network in proposed 3 countries. The study findings will help establish a better understanding in signs, symptoms, medical history and circumstances preceding death; prioritize future interventions for early and effective diagnostics and treatment for diseases and how to keep mortality surveillance ongoing in study rural settings.

NCT ID: NCT04532463 Recruiting - Clinical trials for Cryptococcal Meningitis

Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis

Start date: October 1, 2020
Phase:
Study type: Observational

To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.

NCT ID: NCT04406337 Recruiting - Osteoarthritis Clinical Trials

Low Intensity Pulsed Ultrasound Versus High Intensity Continuous Ultrasound Therapy in Knee Osteoarthritis

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

To compare the effects of low intensity pulsed ultrasound with high intensity continuous ultrasound in knee osteoarthritis

NCT ID: NCT04210141 Suspended - Clinical trials for Daboia Siamensis Envenoming

Optimal Dose of Antivenom for Daboia Siamensis Envenomings

ODADS
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

The aim of the study is to identify an 'optimal' initial dosing of the new Burma Pharmaceutical Industry (BPI) lyophilized mono-specific antivenom for patients with systemic Daboia siamensis envenoming. The initial dosing will aim to reverse venom-induced coagulopathy (as demonstrated by a negative 20 minutes Whole Blood Clotting Time (20WBCT) at 6 hours in 95% of patients whilst causing less than 5% anaphylactic reaction.

NCT ID: NCT04132479 Completed - Clinical trials for Helicobacter Pylori Infection

The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar

Start date: January 1, 2018
Phase: Phase 4
Study type: Interventional

This study aims to: 1. Determine the prevalence of Helicobacter infection in Myanmar (this would be the largest ever series in the country) 2. Determine the clinical and epidemiological associations of Helicobacter infection in Myanmar 3. Determine the utility of stool antigen testing to diagnose the infection and confirm eradication 4. Compare the relative efficacies of concomitant and sequential therapy 5. Determine the relative efficacies of first, second and third line therapies in Myanmar in 2018

NCT ID: NCT04089436 Active, not recruiting - Encephalitis Clinical Trials

SouthEast Asia Encephalitis Project

SEAe
Start date: July 15, 2014
Phase:
Study type: Observational [Patient Registry]

Encephalitis, an acute inflammation of the central nervous system associated with neurologic dysfunction is of public health concern worldwide, because of its high mortality and neurological sequelae rates. In Asia where many of the possible etiologies are of major public health concerns (i.e. dengue, Japanese encephalitis, West Nile virus, EV71), acute encephalitis is among the most frequent and severe causes of pediatric hospitalization. Despite extensive microbiological investigations, no pathogen is identified for a significant proportion of encephalitis patients in both industrialized and developing countries (28-85% of cases remain unconfirmed). Unknown and sometimes new emerging infectious agents may be responsible for cases of currently unknown etiology and an intensive effort to identify and characterize them is to be done. From this perspective, the Southeast Asian region, a particularly significant biodiversity hotspot, is at high risk for new pathogen emergence. Surveillance and diagnostic capabilities for encephalitis remain poor and still suffer from serious shortcomings in most Southeast Asian countries and beyond. Although the burden of non-infectious encephalitis in this region remains to be ascertained, the best laboratories only identify etiological infective agents in less than half of patients. Systematic data regarding the contribution of these diseases are lacking and to define the burden of these infections, to describe the full clinical spectrum and characteristics of acute central nervous system infections, and to develop diagnostic and therapeutic algorithms to improve patient care. The proposed project is an ambitious and multidisciplinary research consortium that aims to reduce the morbidity and mortality associated with infectious encephalitis in Southeast Asia (Cambodia, Laos, Vietnam and Myanmar) by improving diagnosis and medical care for patients. The SEAe project specific objectives are: - To fill‐in the biomedical knowledge gaps regarding acute encephalitis syndrome; - To strengthen hospital laboratories capacities to enhance health by improving diagnosis and care for patients; - To identify unknown pathogens responsible for encephalitis; - To provide reliable information and a sustainable regional and sub‐regional surveillance network to clinicians and public health stakeholders that will help them to better define prevention policies, vaccination strategy, and build preparedness to emerging infectious risks.

NCT ID: NCT03939013 Completed - Hepatitis C Clinical Trials

Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar)

CT2
Start date: January 30, 2019
Phase: N/A
Study type: Interventional

Implementation-effectiveness hybrid trial assessing acceptability, feasibility and cost-effectiveness of community-based point-of-care testing and treatment for hepatitis C. Utilises Cepheid GeneXpert HCV VL device as diagnostic tool (diagnosis of chronic infection and assessment of treatment outcome) and sofosbuvir/daclatasvir for HCV therapy (local standard of care).

NCT ID: NCT03847870 Completed - Clinical trials for Rickettsiae Infections

Rickettsiae in Myanmar

Rickettsiae
Start date: June 20, 2019
Phase:
Study type: Observational

Rickettsial infections have been found to be the second most common cause of non-malarial febrile illness in Southeast Asia, just after dengue, and are largely neglected treatable causes of morbidity and mortality. The rickettsiae can be divided into three major groups: the scrub typhus group (STG), the typhus group (TG) and the spotted fever group (SFG). Rickettsial infections typically present with an acute fever and are difficult to diagnose due to the many different causes of undifferentiated fever in Southeast Asia. Rickettsial IgG seroprevalence, reflecting past infection, will give an estimate of the burden of rickettsial infections in the population. Background seroprevalence studies in countries around Myanmar have found high rates of rickettsial infections. Yet, in Myanmar there have been no prevalence studies on rickettsial infections since the Second World War. We plan to determine IgG levels to the three different groups of rickettsial infections in leftover blood samples in several clinics and hospitals in different regions of Myanmar.

NCT ID: NCT03648411 Completed - Clinical trials for Asymptomatic Infections

Drug Resistance Among Asymptomatic Infection

Start date: January 12, 2019
Phase:
Study type: Observational

A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.